Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | FASN | P49327 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | CSF1R | P07333 | 2/20 | 0.58 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NPY1R | P25929 | 1/20 | 0.53 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CTSV | O60911 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | MAP2 | P11137 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392327 | 1.00 | MAPT (0.68) | MAPTFASNMEN1KMT2ACSF1R | |
| SCHEMBL18102160 | 0.86 | MAPT (0.81) | MAPTFASNMEN1KMT2ACSF1R | |
| SCHEMBL6481461 | 0.82 | PADI4 (0.70) | MAPTFASNPADI4 | |
| SCHEMBL6481459 | 0.82 | PADI4 (0.70) | MAPTFASNPADI4 | |
| SCHEMBL19952906 | 0.81 | PADI4 (0.73) | MAPTMEN1KMT2ACSF1RALDH1A1 | |
| SCHEMBL3944802 | 0.81 | MAPT (1.00) | MAPTFASNMEN1KMT2ACSF1R | |
| SCHEMBL29612310 | 0.81 | PADI4 (0.73) | MAPTMEN1KMT2ACSF1RALDH1A1 | |
| SCHEMBL32665949 | 0.81 | FASN (0.70) | MAPTFASNMEN1KMT2ACSF1R | |
| SCHEMBL4469573 | 0.80 | FASN (1.00) | MAPTFASNMEN1KMT2ACSF1R | |
| SCHEMBL31061146 | 0.80 | FASN (1.00) | MAPTFASNMEN1KMT2ACSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112390750-B | Quinolinone compounds as selective phosphodiesterase 2 inhibitors and preparation method thereof | 常州大学 | 2022-03-01 | — | — | CN | disclosed |
| CN-112390750-A | Quinolinone compounds as selective phosphodiesterase 2 inhibitors and preparation method thereof | 常州大学 | 2021-02-23 | — | — | CN | disclosed |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180044324-A1 | Quinolinones as Inhibitors of Translation Initiation Complex | Sanford Burnham Prebys Medical Discovery Institute | 2018-02-15 | — | — | US | disclosed |
| US-20180044324-A1 | Quinolinones as Inhibitors of Translation Initiation Complex | Sanford Burnham Prebys Medical Discovery Institute | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044324-A1 | Quinolinones as Inhibitors of Translation Initiation Complex | EIF4E, EIF4A1, EIF4A2 | MAPT 1569/4885FASN 2439/4885MEN1 3781/4885 |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | EIF4E, EIF4A1, EIF4A2 | MAPT 1569/4885FASN 2439/4885MEN1 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.